Investigating the role of a specific FOXP3 protein variant in asthma severity
Official title: FOXP3 ΔE2 isoform in asthma severity and persistence
Funded at Indiana University Indianapolis · NIH-11103365 · Data updated 2026-11-12
This study is looking at a special version of a protein that might affect how severe and long-lasting asthma can be, using mice to learn more about how it impacts the immune system and allergy symptoms, which could help find new ways to treat asthma for people like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | June 4, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $776,962 |
| NIH project number | 5R01AI180518-02 |
| Project ID | NIH-11103365 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with persistent asthma or severe allergic reactions.
✕Less likely to help
Patients with asthma that is well-controlled or those without allergic components may not benefit from this research.
What this research studies
This research focuses on understanding how a specific variant of the FOXP3 protein, known as the ΔE2 isoform, affects the severity and persistence of asthma. By using specially developed mouse models, the researchers will explore how this variant influences the immune response, particularly in relation to allergic airway inflammation. The study aims to identify the mechanisms by which the ΔE2 isoform contributes to asthma symptoms, potentially leading to new therapeutic strategies. Patients may benefit from insights gained about the role of FOXP3 in asthma management.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that better manage asthma symptoms and improve patient quality of life.
How similar studies have gone: While the specific focus on the FOXP3 ΔE2 isoform is novel, previous research has shown that targeting immune regulatory pathways can lead to significant advancements in asthma treatment.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Zhou, Baohua — Indiana University Indianapolis
- Study coordinator: Zhou, Baohua
Related research
Other NIH-funded projects on the same topics.
-
GLP-1 receptor agonists as immune targets to treat asthma in lean and obese adults
Aims to understand how GLP-1R‑agonist diabetes medicines may directly calm immune cells to reduce asthma in adults who are lean or obese.
-
Understanding how a type of immune cell called ILC2s affect asthma in adults
This grant studies how group 2 innate lymphoid cells influence asthma in adults to help identify new ways to manage airway inflammation.
-
Expanding understanding of asthma in kids through airways and blood profiling
A study at UC San Francisco will profile blood and nasal/sputum samples from 300 youth (including 200 with asthma) over a year to understand how environmental and social factors influence asthma in marginalized communities.
-
Preventing and improving asthma care for children in urban communities
This program will try several approaches — from giving helpful bacteria to babies to allergy immunotherapy and advanced airway testing — to prevent and better treat asthma in children who live in cities.
-
IDEAL project helps predict vaccine response, infections, and asthma in early childhood
A Child-focused program will collect and share saliva, blood, and tissue samples from diverse infants to find biological patterns that predict how vaccines work, how respiratory infections occur, and who develops asthma.
-
Understanding how early-life immune development affects vaccine responses and asthma risk in children
This project uses lab-grown human immune cells from infants and young children to explore why some kids respond poorly to vaccines and are more prone to respiratory infections and asthma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.